These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12803575)

  • 1. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
    Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
    Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
    De Kesel PM; Lambert WE; Stove CP
    Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
    Perera V; Gross AS; Xu H; McLachlan AJ
    J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
    Perera V; Gross AS; McLachlan AJ
    Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?
    Spigset O; Hägg S; Söderström E; Dahlqvist R
    Pharmacogenetics; 1999 Jun; 9(3):409-12. PubMed ID: 10471076
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
    Spigset O; Hägg S; Söderström E; Dahlqvist R
    Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
    Fuhr U; Rost KL
    Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
    Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
    Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
    Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
    Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
    Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
    Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.
    Perera V; Gross AS; Forrest A; Landersdorfer CB; Xu H; Ait-Oudhia S; McLachlan AJ
    Drug Metab Dispos; 2013 Nov; 41(11):1957-66. PubMed ID: 23996078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians.
    Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
    Eur J Clin Pharmacol; 2000 May; 56(2):159-65. PubMed ID: 10877011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers.
    Simon T; Becquemont L; Hamon B; Nouyrigat E; Chodjania Y; Poirier JM; Funck-Brentano C; Jaillon P
    Br J Clin Pharmacol; 2001 Nov; 52(5):601-4. PubMed ID: 11736870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers.
    Chen Y; Tu JH; He YJ; Zhang W; Wang G; Tan ZR; Zhou G; Fan L; Zhou HH
    Xenobiotica; 2009 Jul; 39(7):508-13. PubMed ID: 19534587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
    De Kesel PM; Lambert WE; Stove CP
    Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.
    Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I
    Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
    Rasmussen BB; Brøsen K
    Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
    Wang X; Yeung JH
    J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.
    Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U
    Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
    Faber MS; Jetter A; Fuhr U
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.